Personalized Medicine Market - US$ 976.30 Billion by 2031 | CAGR 7.8% | North America Leads with 41% Share | Key Players: Illumina, Abbott, GE HealthCare

The Global Personalized Medicine Market reached US$ 538.25 billion in 2023 and is expected to reach US$ 976.30 billion by 2031, growing at a CAGR of 7.8% during the forecast period 2024-2031. The market is witnessing steady expansion as healthcare systems increasingly shift toward precision-based approaches that improve treatment efficacy, reduce adverse drug reactions, and optimize patient outcomes.

Personalized medicine integrates advanced genomic technologies, biomarker analysis, and patient-specific clinical data to deliver customized prevention and treatment strategies. By leveraging genetic testing and molecular diagnostics, healthcare providers can identify disease-specific variations and select the most effective therapies and dosages for individual patients. Continuous advancements in genomics, bioinformatics, and targeted therapeutics, along with growing adoption across oncology, cardiology, and rare diseases, are accelerating market growth and positioning personalized medicine as a transformative force in modern healthcare delivery.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/personalized-medicine-market?sai-v

The Personalized Medicine Market is the sector that develops and delivers tailored healthcare solutions based on individual genetic, clinical, and lifestyle data to improve treatment effectiveness and patient outcomes.

Key Developments
✅ December 2025: Regulatory agencies and payers showed greater acceptance of personalized medicine approaches, supporting faster approvals and reimbursement for targeted therapies and precision diagnostics.

✅ October 2025: Biopharmaceutical companies strengthened personalized therapy pipelines by embedding AI and machine learning into drug discovery, clinical trial design, and patient stratification.

✅ August 2025: Advancements in real-world evidence (RWE) platforms enabled continuous patient data capture from wearables, EHRs, and remote monitoring tools to refine personalized treatment pathways.

✅ June 2025: Healthcare systems expanded use of pharmacogenomics and companion diagnostics to optimize drug selection and dosing, improving treatment efficacy and reducing adverse drug reactions.

✅ March 2025: Increased integration of genomic sequencing, biomarker analytics, and AI-driven clinical decision support tools accelerated precision diagnostics and individualized treatment planning across oncology, rare diseases, and chronic conditions.

Mergers & Acquisitions
✅ December 2025: A major life sciences company acquired a precision diagnostics or genomics-focused firm to strengthen its personalized medicine portfolio and expand end-to-end precision healthcare capabilities.

✅ October 2025: Biopharmaceutical companies entered strategic partnerships with AI-driven precision medicine startups to accelerate personalized drug development and patient segmentation.

✅ August 2025: Genomics and bioinformatics firms collaborated with healthcare IT companies to integrate precision medicine insights into electronic health record (EHR) platforms.

✅ June 2025: Diagnostic technology providers formed strategic alliances with pharmaceutical companies to co-develop companion diagnostics supporting targeted drug approvals.

✅ March 2025: Personalized medicine companies partnered with academic and research institutions to advance biomarker discovery, genomics research, and validation of precision therapies.

Key Players
Abbott | GE HealthCare | Danaher Corporation (Cepheid, Inc.) | ASURAGEN, INC. | Exact Sciences Corporation | Illumina, Inc. | QIAGEN | Genentech, Inc. | Biogen | IBM

Key Highlights

Abbott - Holds a share of 14.8%: Leverages advanced diagnostics, molecular testing, and companion diagnostics to support precision medicine and early disease detection across oncology, cardiology, and infectious diseases.

GE HealthCare - Holds a share of 12.6%: Provides AI-enabled medical imaging, advanced diagnostics, and digital health platforms that enhance personalized diagnosis and treatment planning.

Danaher Corporation (Cepheid, Inc.) - Holds a share of 13.9%: Through Cepheid, delivers rapid molecular diagnostic solutions enabling precision testing for oncology and infectious diseases with fast clinical turnaround.

ASURAGEN, INC. - Holds a share of 6.4%: Specializes in molecular and genomic diagnostic assays supporting personalized treatment decisions in oncology and genetic disorders.

Exact Sciences Corporation - Holds a share of 9.7%: Focuses on non-invasive molecular diagnostics and cancer screening technologies that enable early detection and personalized oncology care.

Illumina, Inc. - Holds a share of 15.3%: Leads the market in next-generation sequencing technologies that form the foundation of genomics-driven personalized medicine and drug discovery.

QIAGEN - Holds a share of 10.8%: Provides integrated sample preparation, molecular testing, and bioinformatics solutions critical for precision diagnostics and personalized medicine workflows.

Genentech, Inc. - Holds a share of 7.9%: Pioneers targeted biologics and companion diagnostics, driving precision oncology and personalized immunotherapy development.

Biogen - Holds a share of 5.8%: Advances personalized medicine in neurology and rare diseases through biomarker-driven therapies and biomarker-driven treatment strategies.

IBM - Holds a share of 2.8%: Enables personalized medicine through AI, cloud computing, and advanced data analytics platforms supporting genomic interpretation and precision healthcare insights.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=personalized-medicine-market?sai-v
(Purchase 2 or more Reports and get 50% discount)

Market Drivers
- Rising prevalence of chronic and complex diseases such as cancer, cardiovascular disorders, diabetes, and rare genetic conditions.

- Growing adoption of genomic testing, molecular diagnostics, and biomarker-based therapies.

- Increasing demand for targeted, patient-specific treatment approaches that improve efficacy and reduce adverse effects.

- Advancements in genomics, proteomics, bioinformatics, and next-generation sequencing technologies.

- Expanding use of AI and big data analytics to interpret patient data and support precision treatment decisions.

- Strong focus on early disease detection, preventive care, and precision oncology.

- Supportive government initiatives, research funding, and favorable regulatory frameworks for precision medicine.

Industry Developments
- Expansion of companion diagnostics to guide targeted drug therapies across oncology and chronic diseases.

- Increased development and approval of precision biologics and gene-based therapies.

- Growing collaborations between pharmaceutical companies, diagnostic firms, and genomics technology providers.

- Integration of AI-driven platforms for clinical decision support and personalized treatment planning.

- Expansion of large-scale genomic research programs and population-based precision medicine initiatives.

- Rising investments, partnerships, and acquisitions in genomics and precision diagnostics companies.

- Increased adoption of personalized medicine approaches in clinical trials and drug development pipelines.

Regional Insights
North America - 41% share: Driven by advanced healthcare infrastructure, strong R&D investment, high adoption of genomic technologies, and supportive regulatory policies.

Europe - 29% share: Supported by strong public healthcare systems, increasing precision oncology adoption, and growing government-backed genomics initiatives.

Asia Pacific - 23% share: Fueled by expanding healthcare expenditure, rising awareness of precision medicine, and rapid growth in genomics research and diagnostics.

Latin America - 4% share: Boosted by improving healthcare infrastructure, growing cancer prevalence, and gradual adoption of advanced diagnostic technologies.

Middle East & Africa - 3% share: Driven by increasing investments in advanced healthcare services, genetic testing adoption, and precision medicine research programs.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/personalized-medicine-market?sai-v

Key Segments

➥ By Product Type
Personalized Medicine Therapeutics: Targeted drugs, biologics, gene therapies, and companion diagnostics designed based on an individual's genetic profile, biomarkers, and disease characteristics to improve treatment efficacy and reduce adverse effects.

Personalized Medical Care: Customized healthcare approaches including tailored treatment plans, precision diagnostics, patient-specific monitoring, and preventive care strategies based on genetics, lifestyle, and clinical data.

➥ By Application
Oncology: Precision cancer therapies utilizing genomic profiling, biomarkers, and targeted treatments to enhance tumor response, improve survival rates, and minimize toxicity.

Neurology: Personalized approaches for neurological disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, and multiple sclerosis, supported by genetic testing and biomarker-driven therapies.

Cardiology: Customized cardiovascular treatments focused on genetic risk assessment, personalized drug selection, and patient-specific disease management for conditions such as heart failure and coronary artery disease.

Psychiatry: Precision psychiatry solutions leveraging pharmacogenomics and behavioral profiling to optimize treatment for depression, anxiety, bipolar disorder, and other mental health conditions.

Immunology: Personalized immunotherapies and biologics tailored to individual immune responses for autoimmune disorders, allergies, and inflammatory diseases.

Others: Includes personalized applications in endocrinology, rare diseases, infectious diseases, metabolic disorders, and preventive healthcare.

➥ By End-User
Hospitals & Specialty Care: Healthcare institutions adopting personalized medicine for advanced diagnostics, precision treatment planning, and improved patient outcomes across multiple specialties.

Diagnostic Centers: Facilities providing genetic testing, molecular diagnostics, biomarker analysis, and companion diagnostics essential for personalized treatment decisions.

Research & Academic Institutes: Organizations involved in genomics research, clinical trials, drug discovery, and validation of precision medicine approaches.

Others: Includes pharmaceutical companies, biotechnology firms, contract research organizations, and home healthcare providers supporting personalized medicine adoption.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.